09 May 2018 Genmab Announces U.S. FDA Approval of DARZALEX® (daratumumab) in Newly Diagnosed Multiple Myeloma
07 May 2018 OSE Immunotherapeutics Presents New Data on OSE-127 at the American Association of Immunologists (AAI) Annual Meeting May 4-8 2018 in Austin, Texas
07 May 2018 FDA Grants Priority Review to Genentech’s Cancer Immunotherapy Tecentriq (Atezolizumab) for Initial Treatment of People With a Specific Type of Metastatic Lung Cancer
05 May 2018 Evolve Biologics™ Reaches Major Milestones in Phase III Trial for PlasmaCap™ IG (Intravenous Immunoglobulin), Including Dosing of First Pediatric Patient
04 May 2018 CStone announces first patient dosed with anti-CTLA-4 antibody CS1002 of a Phase I study in Australia
03 May 2018 European Medicines Agency Validates Bristol-Myers Squibb’s Type II Variation Application for Opdivo Plus Yervoy Combination for Treatment of First-Line Metastatic Non-Small Cell Lung Cancer (NSCLC)
03 May 2018 Merck Provides Update on KEYNOTE-407 Trial
03 May 2018 Sandoz receives complete response letter from the US FDA for proposed biosimilar rituximab
03 May 2018 New data from Biotest's monoclonal antibody-drug-conjugate (ADC) BT-062 in the therapy of solid tumors
02 May 2018 NeoImmuneTech Announces a Clinical Trial Collaboration with a Global Leading Pharmaceutical Company to Evaluate HyLeukin-7 in Combination with a PD-L1 Checkpoint Inhibitor in Advanced High-Risk Skin Cancers
02 May 2018 Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atopic dermatitis patients
01 May 2018 AbbVie Submits Marketing Authorization Application to the European Medicines Agency for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis
01 May 2018 Aptevo Therapeutics Announces IND Submission for APVO436
30 Apr 2018 Prometic Reports Positive Clinical Data from its Intravenous Immunoglobulin (IVIG) Pivotal Phase 3 Trial
30 Apr 2018 FDA Grants Priority Review to Merck’s sBLA for KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed (ALIMTA®) and Platinum Chemotherapy Based on Results from Phase 3 KEYNOTE-189 Trial as First-Line Treatment of Metastatic Nonsquamous NSCLC
30 Apr 2018 Ablynx completes patient recruitment in the phase IIb RESPIRE study of its inhaled anti-RSV nanobody ALX-0171
30 Apr 2018 FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma
28 Apr 2018 Amgen Receives Positive CHMP Opinion To Expand Use Of Prolia® (denosumab) To Patients With Glucocorticoid-Induced Osteoporosis
28 Apr 2018 Bolder BioTechnology Announces Positive Results from Phase 1 Clinical Trial of BBT-015, a Long-Acting G-CSF Analog, in Healthy Volunteers
28 Apr 2018 UCB Announces Positive CHMP Opinion for CIMZIA® (certolizumab pegol) in Patients with Moderate-to-Severe Plaque Psoriasis
27 Apr 2018 FDA Grants Breakthrough Therapy Designation to Omeros’ MASP-2 Inhibitor OMS721 for the Treatment of High-Risk Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
27 Apr 2018 ImmunoGen Announces Successful Completion of Interim Analysis for FORWARD I Phase 3 Trial of Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
27 Apr 2018 Sutro Initiates First Clinical Trial of CD74-Targeting ADC for Lymphoma & Multiple Myeloma Treatment; The First of a New Generation of Precisely Engineered ADCs
27 Apr 2018 Corvus Pharmaceuticals Announces Initiation of Phase 1/1b Clinical Trial of Investigational Anti-CD73 Antibody, CPI-006, in Patients with Advanced Cancer
27 Apr 2018 ThromboGenics Initiates Phase 2 Clinical Study Evaluating anti-PlGF (THR-317) in combination with anti-VEGF (ranibizumab) for treatment of Diabetic Macular Edema (DME)

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up